NCT03765008

Brief Summary

There is a growing body of evidence suggesting low water intake and elevated levels of the hormone vasopressin exacerbate glucose regulation. This project will examine the physiological mechanism by which low water intake impairs glucose homeostasis. In the current proposal we aim to: 1) quantify the degree of glucose impairment as a response to elevated vasopressin due to low water intake and 2) identify the physiological mechanism by which elevated vasopressin, as a response to low water intake, impairs glucose regulation

Trial Health

15
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Feb 2019

Shorter than P25 for not_applicable

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 3, 2018

Completed
2 days until next milestone

First Posted

Study publicly available on registry

December 5, 2018

Completed
2 months until next milestone

Study Start

First participant enrolled

February 11, 2019

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 3, 2019

Completed
26 days until next milestone

Study Completion

Last participant's last visit for all outcomes

April 29, 2019

Completed
Last Updated

August 28, 2019

Status Verified

August 1, 2019

Enrollment Period

2 months

First QC Date

December 3, 2018

Last Update Submit

August 23, 2019

Conditions

Keywords

watervasopressin

Outcome Measures

Primary Outcomes (4)

  • amount of glucose metabolized M

    amount of glucose metabolized during the euglycemic \& Hyperglycemic clamp

    220-240 min & 340-360 min of the protocol

  • metabolic clearance rate for insulin

    metabolic clearance rate for insulin during the euglycemic \& Hyperglycemic clamp

    220-240 min & 340-360 min of the protocol

  • quantity of glucose metabolized per unit plasma insulin concentration

    quantity of glucose metabolized per unit plasma insulin concentration during the euglycemic \& Hyperglycemic clamp

    220-240 min & 340-360 min of the protocol

  • Rate of glucose appearance & disappearance

    Rate of glucose appearance \& disappearance during the euglycemic \& Hyperglycemic clamp

    220-240 min & 340-360 min of the protocol

Secondary Outcomes (3)

  • Plasma copeptin

    0 min, 240 min & 360 min of the protocol

  • glucagon

    0 min, 240 min & 360 min of the protocol

  • Cortisol

    0 min, 240 min & 360 min of the protocol

Study Arms (2)

High Water intake

ACTIVE COMPARATOR

5-days of High water intake according to IOM guidelines

Other: Water intake manipulation

Low Water Intake

EXPERIMENTAL

5-days of Low water intake of 500 mL/day

Other: Water intake manipulation

Interventions

for 5 days prior to each experiment subjects will undergo manipulation of their water intake.

High Water intakeLow Water Intake

Eligibility Criteria

Age30 Years - 55 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • BMI 27.5-35

You may not qualify if:

  • BMI \<27.5 or \>35
  • high physical activity
  • diabetes
  • impaired liver or kidney function
  • cardiovascular disease
  • weight change of more than 3 kg in the past month
  • pregnancy
  • previous surgery on digestive tract (except appendectomy)
  • serotonin re-uptake inhibitors.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Glucose Metabolism DisordersDehydrationDiabetes Insipidus

Condition Hierarchy (Ancestors)

Metabolic DiseasesNutritional and Metabolic DiseasesWater-Electrolyte ImbalancePathologic ProcessesPathological Conditions, Signs and SymptomsKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesPituitary DiseasesEndocrine System Diseases
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor of Nutrition

Study Record Dates

First Submitted

December 3, 2018

First Posted

December 5, 2018

Study Start

February 11, 2019

Primary Completion

April 3, 2019

Study Completion

April 29, 2019

Last Updated

August 28, 2019

Record last verified: 2019-08

Data Sharing

IPD Sharing
Will not share